Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EHA 2022 | COVALENT-101: BMF-219 in patients with R/R AML, DLBCL & multiple myeloma

Farhad Ravandi • 11 Jun 2022

EHA 2022

Acute Myeloid Leukemia Diffuse Large B-Cell Lymphoma Leukemia Lymphoma Multiple Myeloma Non-Hodgkin Lymphoma BMF-219

COVALENT-101

Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the rationale and design of the COVALENT-101 study (NCT05153330) which evaluates the tolerability and efficacy of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding – BMS/Celgene, Amgen, Astex/Taiho, Syros, Prelude, Abbvie, Xencor Consultant – BMS, Abbvie, Novartis, AstraZeneca, Taiho, Jazz

The value of MRD as a marker for disease eradication in AML

Farhad Ravandi • 8 Dec 2023

Azacitidine and venetoclax plus gilteritinib in the treatment of FLT3-mutated AML

Farhad Ravandi • 8 Dec 2023

Poor outcomes of patients with AML who relapse underscores the need for effective initial treatment

Farhad Ravandi • 8 Dec 2023

Nelarabine, PEG-asparaginase and venetoclax added to HCVAD in T-ALL/T-LBL

Farhad Ravandi • 8 Dec 2023

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024